Neuroprotective Effect of Long-term NDI1 Gene Expression in a Chronic Mouse Model of Parkinson Disorder
- 1 August 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in Rejuvenation Research
- Vol. 12 (4) , 259-267
- https://doi.org/10.1089/rej.2009.0854
Abstract
Previously, we showed that the internal rotenone-insensitive nicotinamide adenine dinucleotide (NADH)-quinone oxidoreductase (NDI1) gene from Saccharomyces cerevisiae (baker's yeast) can be successfully inserted into the mitochondria of mice and rats and the expressed enzyme was found to be fully functional. In this study, we investigated the ability of the Ndi1 enzyme to protect the dopaminergic neurons in a chronic mouse model of Parkinson disorder. After expression of the NDI1 gene in the unilateral substantia nigra of male C57BL/6 mice for 8 months, a chronic Parkinsonian model was created by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) with probenecid and evaluated using neurochemical and behavioral responses 1–4 weeks post-MPTP/probenecid injection. We showed that expression of Ndi1 was able to significantly prevent the loss of dopamine and tyrosine hydroxylase as well as the dopaminergic transporters in the striatum of the chronic Parkinsonian mice. Behavioral assessment based on a methamphetamine-induced rotation test and spontaneous swing test further supported neurological preservation in the NDI1-treated Parkinsonian mice. The data presented in this study demonstrate a protective effect of the NDI1 gene in dopaminergic neurons, suggesting its therapeutic potential for Parkinson-like disorders.Keywords
This publication has 44 references indexed in Scilit:
- Current status of gene therapy trials for Parkinson's diseaseExperimental Neurology, 2008
- Protection by the NDI1 Gene against Neurodegeneration in a Rotenone Rat Model of Parkinson's DiseasePLOS ONE, 2008
- Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neuronsProceedings of the National Academy of Sciences, 2007
- Possibility of transkingdom gene therapy for Complex I diseasesBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2006
- Can a Single Subunit Yeast NADH Dehydrogenase (Ndi1) Remedy Diseases Caused by Respiratory Complex I Defects?Rejuvenation Research, 2006
- Functional Expression of the Single Subunit NADH Dehydrogenase in Mitochondria In Vivo: A Potential Therapy for Complex I DeficienciesHuman Gene Therapy, 2004
- Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated micePublished by Elsevier ,2002
- Targets for Gene Therapy of Parkinson's Disease: Growth Factors, Signal Transduction, and PromotersExperimental Neurology, 1997
- MPTP mechanisms of neurotoxicity and their implications for Parkinson's diseaseEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983